Altimmune, Inc. (ALT) Earnings History
Annual and quarterly earnings data from 2005 to 2025
Loading earnings history...
ALT EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
ALT Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 0.0% | -230461.0% | -214861.0% |
| 2024 | 100.0% | -515860.0% | -475295.0% |
| 2023 | 100.0% | -22518.5% | -20762.2% |
| 2022 | - | - | - |
| 2021 | 100.0% | -2197.6% | -2201.6% |
Download Data
Export ALT earnings history in CSV or JSON format
Free sign-in required to download data
Altimmune, Inc. (ALT) Earnings Overview
As of May 8, 2026, Altimmune, Inc. (ALT) reported trailing twelve-month net income of -$88M, reflecting +25.4% year-over-year growth. The company earned $-0.88 per diluted share over the past four quarters, with a net profit margin of -214861.0%.
Looking at the long-term picture, ALT's historical earnings data spans multiple years. The company achieved its highest annual net income of $194M in fiscal 2016.
Altimmune, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including VKTX (-$472M net income), TERN (-$94M net income), NRXP (-$38M net income, -2336.5% margin), ALT has comparable earnings metrics. Compare ALT vs VKTX →
ALT Earnings vs Peers
Earnings metrics vs comparable public companies
ALT Historical Earnings Data (2005–2025)
21 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$88M | +7.3% | -$94M | $-1.00 | -214861.0% | -230461.0% |
| 2024 | -$95M | -7.5% | -$103M | $-1.34 | -475295.0% | -515860.0% |
| 2023 | -$88M | -4.4% | -$96M | $-1.66 | -20762.2% | -22518.5% |
| 2022 | -$85M | +12.7% | -$88M | $-1.81 | - | - |
| 2021 | -$97M | -98.0% | -$97M | $-2.35 | -2201.6% | -2197.6% |
| 2020 | -$49M | -139.0% | -$55M | $-1.91 | -599.2% | -669.5% |
| 2019 | -$21M | +47.6% | -$21M | $-1.56 | -353.7% | -370.0% |
| 2018 | -$39M | +15.6% | -$43M | $-13.98 | -379.2% | -414.6% |
| 2017 | -$46M | -123.9% | -$52M | $-108.77 | -111860.3% | -125401.2% |
| 2016 | $194M | +5734.1% | -$11M | $-49.80 | 3706.4% | -215.4% |
See ALT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ALT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ALT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonALT — Frequently Asked Questions
Quick answers to the most common questions about buying ALT stock.
Is ALT growing earnings?
ALT EPS is $-0.88, with earnings growth accelerating to +25.4%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-88M.
What are ALT's profit margins?
Altimmune, Inc. net margin is -214861.0%, with operating margin at -230461.0%. Below-average margins reflect competitive or cost pressures.
How consistent are ALT's earnings?
ALT earnings data spans 2005-2025. The accelerating earnings trend is +25.4% YoY. Historical data enables comparison across business cycles.